179 related articles for article (PubMed ID: 27260937)
1. Initiation of strong prescription opioids in Australia: cohort characteristics and factors associated with the type of opioid initiated.
Gisev N; Pearson SA; Blanch B; Larance B; Dobbins T; Larney S; Degenhardt L
Br J Clin Pharmacol; 2016 Oct; 82(4):1123-33. PubMed ID: 27260937
[TBL] [Abstract][Full Text] [Related]
2. A population-based study of transdermal fentanyl initiation in Australian clinical practice.
Gisev N; Pearson SA; Larance B; Larney S; Blanch B; Degenhardt L
Eur J Clin Pharmacol; 2019 Mar; 75(3):401-408. PubMed ID: 30392109
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and incidence of prescription opioid analgesic use in Australia.
Lalic S; Ilomäki J; Bell JS; Korhonen MJ; Gisev N
Br J Clin Pharmacol; 2019 Jan; 85(1):202-215. PubMed ID: 30338545
[TBL] [Abstract][Full Text] [Related]
4. Anticipating the effects of restricting high-dose preparations of strong opioids in Australia: A population-based analysis to inform the current policy debate.
Zheng D; Narayan SW; Zoega H; Litchfield M; Buckley NA; Pearson SA; Schaffer AL
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):521-527. PubMed ID: 30790376
[TBL] [Abstract][Full Text] [Related]
5. Transition to high-dose or strong opioids: a population-based study of people initiating opioids in Australia.
Lalic S; Gisev N; Bell JS; Ilomäki J
Addiction; 2020 Jun; 115(6):1088-1097. PubMed ID: 31814212
[TBL] [Abstract][Full Text] [Related]
6. Predictors of persistent prescription opioid analgesic use among people without cancer in Australia.
Lalic S; Gisev N; Bell JS; Korhonen MJ; Ilomäki J
Br J Clin Pharmacol; 2018 Jun; 84(6):1267-1278. PubMed ID: 29451672
[TBL] [Abstract][Full Text] [Related]
7. Changes in trends and pattern of strong opioid prescribing in primary care.
Zin CS; Chen LC; Knaggs RD
Eur J Pain; 2014 Oct; 18(9):1343-51. PubMed ID: 24756859
[TBL] [Abstract][Full Text] [Related]
8. Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims.
Karanges EA; Blanch B; Buckley NA; Pearson SA
Br J Clin Pharmacol; 2016 Jul; 82(1):255-67. PubMed ID: 26991673
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical opioid poisonings in Victoria, Australia: Rates and characteristics of a decade of emergency department presentations among nine pharmaceutical opioids.
Lam T; Hayman J; Berecki-Gisolf J; Sanfilippo P; Lubman DI; Nielsen S
Addiction; 2022 Mar; 117(3):623-636. PubMed ID: 34338377
[TBL] [Abstract][Full Text] [Related]
10. Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia.
Schaffer AL; Buckley NA; Degenhardt L; Larance B; Cairns R; Dobbins TA; Pearson SA
CMAJ; 2018 Mar; 190(12):E355-E362. PubMed ID: 29581162
[TBL] [Abstract][Full Text] [Related]
11. Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study.
Schaffer AL; Karanges EA; Buckley NA; Wilson A; Degenhardt L; Larance B; Pearson SA
Pharmacoepidemiol Drug Saf; 2019 Jan; 28(1):97-105. PubMed ID: 30421838
[TBL] [Abstract][Full Text] [Related]
12. Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Victoria, Australia from 2013 to 2018.
Nielsen S; Crossin R; Middleton M; Lam T; Wilson J; Scott D; Martin C; Smith K; Lubman D
Addiction; 2020 Jun; 115(6):1075-1087. PubMed ID: 31742765
[TBL] [Abstract][Full Text] [Related]
13. Prescription of opioid analgesics and related harms in Australia.
Roxburgh A; Bruno R; Larance B; Burns L
Med J Aust; 2011 Sep; 195(5):280-4. PubMed ID: 21895598
[TBL] [Abstract][Full Text] [Related]
14. A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets.
Rubino M; Summers KH; Puenpatom A; Fu C; Ohsfeldt RL; Ben-Joseph RH
J Manag Care Pharm; 2011 Jun; 17(5):367-76. PubMed ID: 21657806
[TBL] [Abstract][Full Text] [Related]
15. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
16. Opioid and analgesic utilization in Ireland in 2000 and 2015: A repeated cross-sectional study.
Moriarty F; Bennett K; Fahey T
Pharmacol Res Perspect; 2022 Jan; 10(1):e00899. PubMed ID: 34913613
[TBL] [Abstract][Full Text] [Related]
17. Opioid analgesic prescribing in Australia: a focus on gender and age.
Hollingworth SA; Gray PD; Hall WD; Najman JM
Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):628-36. PubMed ID: 25845470
[TBL] [Abstract][Full Text] [Related]
18. Prescription opioid dispensing in Australian children and adolescents: a national population-based study.
Bell J; Paget SP; Nielsen TC; Buckley NA; Collins J; Pearson SA; Nassar N
Lancet Child Adolesc Health; 2019 Dec; 3(12):881-888. PubMed ID: 31604614
[TBL] [Abstract][Full Text] [Related]
19. Concomitant inpatient prescribing of strong opioids with sedatives: Associations with comorbid conditions.
Li RJ; Caughey GE; Shakib S
Pharmacol Res Perspect; 2021 Feb; 9(1):e00717. PubMed ID: 33550717
[TBL] [Abstract][Full Text] [Related]
20. [Patterns of prescription of opioid analgesics in Hôtel-Dieu de France of Beyrouth].
Noufi P; Khoury E; Ayoub E; Naccache N; Richa S
Encephale; 2016 Dec; 42(6):511-516. PubMed ID: 27776797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
